Clinical trial
Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A…
NCT00430157 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00430157 |
|---|---|
| Title | Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber |
| Official title | An 8 Day, Randomised, Double Blinded, Placebo-controlled 2-way Crossover Trial of Repeat Doses of Intranasal GSK256066 and Placebo in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rhinitis, Allergic, Seasonal, Seasonal Allergic Rhinitis |
| Intervention type | Drug |
| Interventions | GSK256066 |
| Enrollment | 45 |
| Start date | Jan 1, 2007 |
| First posted | Feb 1, 2007 |
| Last update posted | Jun 4, 2012 |
| Countries | Austria |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: